SMAC模拟物LCL-161在利妥昔单抗耐药B细胞淋巴瘤临床前模型中显示抗肿瘤活性
研究利用利妥昔单抗耐药细胞系及SCID小鼠异种移植模型,评估SMAC模拟物LCL-161的体外和体内抗肿瘤效果。LCL-161剂量依赖性降低IAP水平,与细胞毒化疗协同增强抗肿瘤作用,与RGV方案联用改善耐药模型小鼠生存。
要点
- LCL-161在利妥昔单抗敏感和耐药细胞系中剂量依赖性降低IAP水平。
- LCL-161与细胞毒化疗在体外协同增强抗肿瘤效果。
- LCL-161联合RGV改善耐药细胞系小鼠生存,但敏感细胞系小鼠无此改善。
核心结论
- LCL-161在耐药淋巴瘤体外和体内模型中表现出协同抗肿瘤活性。
- 数据支持进一步开展LCL-161作为新型抗淋巴瘤药物的临床前研究。
研究设计与样本
- 研究使用利妥昔单抗耐药细胞系(RRCLs)和利妥昔单抗敏感细胞系。
- 抗肿瘤效果通过发光法三磷酸腺苷检测、流式细胞术、SCID小鼠异种移植和离体患者活检样本研究确定。
主要发现
- 体外暴露于LCL-161导致利妥昔单抗敏感细胞系和RRCLs中IAP水平剂量依赖性降低。
- LCL-161在利妥昔单抗敏感细胞系和RRCLs中协同增强细胞毒化疗的抗肿瘤效果。
- LCL-161在离体淋巴瘤患者样本中增加蛋白酶体抑制剂卡非佐米的细胞毒作用。
- 在植入RRCLs的严重联合免疫缺陷小鼠中,LCL-161联合利妥昔单抗、吉西他滨和长春瑞滨(RGV)方案较单用RGV改善体内生存。
- 在植入利妥昔单抗敏感细胞系的小鼠中,LCL-161联合RGV未改善生存。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Clinical observations suggest the existence of shared resistance pathways between rituximab and chemotherapy agents. To explore the mechanisms of rituximab resistance, our group created rituximab-resistant cell lines (RRCLs), which display altered expression of several inhibitor of apoptosis (IAP) family proteins. Here, we provide evidence to support pharmacologically targeting IAPs in lymphoma with LCL-161, a small molecule mimetic of the second mitochondria-derived activator of caspases (SMAC). The antitumor effect of LCL-161 was determined using luminescent adenosine triphosphate assays, flow cytometry, SCID mouse xenografts, and ex vivo patient biopsy sample studies. In vitro exposure to LCL-161 also resulted in a dose-dependent decrease in IAP levels, along with synergistic enhancement of the antitumor effect of cytotoxic chemotherapy, in rituximab-sensitive cell lines and RRCLs. In addition, LCL-161 increased the cytotoxic effect of the proteasome inhibitor carfilzomib in ex vivo lymphoma patient samples. The combination of LCL-161 with the chemotherapy regimen rituximab, gemcitabine, and vinorelbine (RGV) improved in vivo survival compared with RGV alone in severe combined immunodeficient mice implanted with RRCLs but not in animals implanted with rituximab-sensitive cell lines. In summary, LCL-161 exhibits synergistic antitumor activity in both in vitro and in vivo models of resistant lymphoma. Our data support further preclinical investigation of LCL-161 as a novel antilymphoma agent.
引用
- Runckel K, Barth MJ, Mavis C, et al. The SMAC mimetic LCL-161 displays antitumor activity in preclinical models of rituximab-resistant B-cell lymphoma. Blood Adv. 2018. PMID: 30530779. doi:10.1182/bloodadvances.2018018168
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。